Setting the tumor volume of the control group as 100%, the tumor volumes of the KS-133 monotherapy, anti-PD-1 antibody monotherapy, and KS-133/anti-PD-1 antibody combination groups were 66%, 50%, and 32%, respectively. Here, PDCD1 is linked to neoplasm.